Second messenger/signal transduction pathways in major mood disorders: Moving from membrane to mechanism of action, part I: Major depressive disorder

CNS Spectrums

Volumn 18, Issue 5, 2013, Pages 231-241

  Niciu, Mark J ^a   Ionescu, Dawn F ^a   Mathews, Daniel C ^a   Richards, Erica M ^a   Zarate, Carlos A ^a,b  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

antidepressants; depression; intracellular cascades; major depressive disorder; secondmessenger; signal transduction

Indexed keywords

BINDING PROTEIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CITALOPRAM; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; DISHEVELLED 1; ELONGATION FACTOR 2 KINASE; FLUOXETINE; FRIZZLED PROTEIN; GLYCOGEN SYNTHASE KINASE 3BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KETAMINE; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; NEUROTROPHIN; P11 PROTEIN; SOMATOMEDIN C; TRANSCRIPTION FACTOR DELTA FOSB; UNCLASSIFIED DRUG; VASCULOTROPIN; WNT PROTEIN;

DRUG MECHANISM; DRUG RESPONSE; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; MAJOR DEPRESSION; MOLECULAR PATHOLOGY; NERVE CELL PLASTICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

DEPRESSIVE DISORDER, MAJOR; HUMANS; SECOND MESSENGER SYSTEMS; SIGNAL TRANSDUCTION;

EID: 84884666321     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852913000059     Document Type: Review

References (81)

1. Sleight AJ, Carolo C, Petit N, Zwingelstein C, Bourson A. Identification of 5-hydroxytryptamine7 receptor binding sites in rat hypothalamus: sensitivity to chronic antidepressant treatment. Mol Pharmacol. 1995; 47(1): 99-103.
2. Svenningsson P, Tzavara ET, Witkin JM, et al. Involvement of striatal and extrastriatal DARPP-32 in biochemical and behavioral effects of fluoxetine (Prozac). Proc Natl Acad Sci USA. 2002; 99(5): 3182-3187. (Pubitemid 34240606)
3. Menkes DB, Rasenick MM, Wheeler MA, Bitensky MW. Guanosine triphosphate activation of brain adenylate cyclase: enhancement by long-term antidepressant treatment. Science. 1983; 219(4580): 65-67. (Pubitemid 13204152)
4. Ozawa H, Rasenick MM. Chronic electroconvulsive treatment augments coupling of the GTP-binding protein Gs to the catalytic moiety of adenylyl cyclase in a manner similar to that seen with chronic antidepressant drugs. J Neurochem. 1991; 56(1): 330-338. (Pubitemid 21901967)
5. Nestler EJ, Terwilliger RZ, Duman RS. Chronic antidepressant administration alters the subcellular distribution of cyclic AMP-dependent protein kinase in rat frontal cortex. J Neurochem. 1989; 53(5): 1644-1647. (Pubitemid 19267038)
6. Nibuya M, Nestler EJ, Duman RS. Chronic antidepressant administration increases the expression of cAMP response element binding protein (CREB) in rat hippocampus. J Neurosci. 1996; 16(7): 2365-2372. (Pubitemid 26154346)
7. Conti AC, Cryan JF, Dalvi A, Lucki I, Blendy JA. cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci. 2002; 22(8): 3262-3268. (Pubitemid 35379213)
8. Thome J, Sakai N, Shin K, et al. cAMP response elementmediated gene transcription is upregulated by chronic antidepressant treatment. J Neurosci. 2000; 20(11): 4030-4036. (Pubitemid 30365673)
9. Zhang HT. Cyclic AMP-specific phosphodiesterase-4 as a target for the development of antidepressant drugs. Curr Pharm Des. 2009; 15(14): 1688-1698.
10. Fujita M, Hines CS, Zoghbi SS, et al. Downregulation of brain phosphodiesterase type IV measured with (11)C-(R)-rolipram positron emission tomography in major depressive disorder. Biol Psychiatry. 2012; 72(7): 548-554.
11. Fleischhacker WW, Hinterhuber H, Bauer H, et al. A multicenter double-blind study of three different doses of the new cAMP-phosphodiesterase inhibitor rolipram in patients with major depressive disorder. Neuropsychobiology. 1992; 26(1-2): 59-64.
12. Fujimaki K, Morinobu S, Duman RS. Administration of a cAMP phosphodiesterase 4 inhibitor enhances antidepressant-induction of BDNF mRNA in rat hippocampus. Neuropsychopharmacology. 2000; 22(1): 42-51.
13. Itoh T, Tokumura M, Abe K. Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats. Eur J Pharmacol. 2004; 498(1-3): 135-142. (Pubitemid 39208072)
14. Tanis KQ, Duman RS. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann Med. 2007; 39(7): 531-544. (Pubitemid 350035570)
15. Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006; 59(12): 1116-1127.
16. Nibuya M, Morinobu S, Duman RS. Regulation of BDNF and trkB mRNA in rat brain by chronic electroconvulsive seizure and antidepressant drug treatments. J Neurosci. 1995; 15(11): 7539-7547.
17. Russo-Neustadt A, Beard RC, Cotman CW. Exercise, antidepressant medications, and enhanced brain derived neurotrophic factor expression. Neuropsychopharmacology. 1999; 21(5): 679-682. (Pubitemid 29486636)
18. Siuciak JA, Lewis DR, Wiegand SJ, Lindsay RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Behav. 1997; 56(1): 131-137. (Pubitemid 27016116)
19. Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002; 22(8): 3251-3261. (Pubitemid 35379212)
20. Monteggia LM, Barrot M, Powell CM, et al. Essential role of brain-derived neurotrophic factor in adult hippocampal function. Proc Natl Acad Sci USA. 2004; 101(29): 10827-10832. (Pubitemid 38955827)
21. Heine VM, Zareno J, Maslam S, Joels M, Lucassen PJ. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci. 2005; 21(5): 1304-1314. (Pubitemid 40516629)
22. Segi-Nishida E, Warner-Schmidt JL, Duman RS. Electroconvulsive seizure and VEGF increase the proliferation of neural stem-like cells in rat hippocampus. Proc Natl Acad Sci USA. 2008; 105(32): 11352-11357.
23. Elfving B, Wegener G. Electroconvulsive seizures stimulate the VEGF pathway via mTORC1. Synapse. 2012; 66(4): 340-345.
24. Greene J, Banasr M, Lee B, Warner-Schmidt J, Duman RS. Vascular endothelial growth factor signaling is required for the behavioral actions of antidepressant treatment: pharmacological and cellular characterization. Neuropsychopharmacology. 2009; 34(11): 2459-2468.
25. Lee JS, Jang DJ, Lee N, et al. Induction of neuronal vascular endothelial growth factor expression by cAMP in the dentate gyrus of the hippocampus is required for antidepressant-like behaviors. J Neurosci. 2009; 29(26): 8493-8505.
26. Isung J, Mobarrez F, Nordstrom P, Asberg M, Jokinen J. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry. 2012; 13(6): 468-473.
27. Ibrahim L, Duncan W, Luckenbaugh DA, et al. Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): a pilot study. Brain Res Bull. 2011; 86(1-2): 129-133.
28. Halmai Z, Dome P, Dobos J, et al. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study. J Affect Disord. 2013; 144(3): 269-273.
29. Minelli A, Zanardini R, Abate M, et al. Vascular endothelial growth factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 2011; 35(5): 1322-1325.
30. Viikki M, Anttila S, Kampman O, et al. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett. 2010; 477(3): 105-108.
31. Tsai SJ, Hong CJ, Liou YJ, et al. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res. 2009; 169(2): 113-117.
32. Clemmons DR. Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer. Nat Rev Drug Discov. 2007; 6(10): 821-833. (Pubitemid 47500506)
33. Lesch KP, Rupprecht R, Muller U, Pfuller H, Beckmann H. Insulin-like growth factor I in depressed patients and controls. Acta Psychiatr Scand. 1988; 78(6): 684-688. (Pubitemid 19027335)
34. Deuschle M, Blum WF, Strasburger CJ, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997; 22(7): 493-503. (Pubitemid 27505109)
35. Weber-Hamann B, Blum WF, Kratzsch J, et al. Insulinlike growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry. 2009; 42(1): 23-28.
36. Mitschelen M, Yan H, Farley JA, et al. Long-term deficiency of circulating and hippocampal insulin-like growth factor I induces depressive behavior in adult mice: a potential model of geriatric depression. Neuroscience. 2011; 185: 50-60.
37. Malberg JE, Platt B, Rizzo SJ, et al. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology. 2007; 32(11): 2360-2368. (Pubitemid 47587671)
38. Park SE, Dantzer R, Kelley KW, McCusker RH. Central administration of insulin-like growth factor-I decreases depressive-like behavior and brain cytokine expression in mice. Journal of Neuroinflammation. 2011; 8: 12.
39. Park SE, Lawson M, Dantzer R, Kelley KW, McCusker RH. Insulin-like growth factor-I peptides act centrally to decrease depression-like behavior of mice treated intraperitoneally with lipopolysaccharide. Journal of Neuroinflammation. 2011; 8: 179.
40. Duman CH, Schlesinger L, Terwilliger R, et al. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res. 2009; 198(2): 366-371.
41. Schilling C, Blum WF, Heuser I, et al. Treatment with antidepressants increases insulin-like growth factor-I in cerebrospinal fluid. J Clin Psychopharmacol. 2011; 31(3): 390-392.
42. Paslakis G, Blum WF, Deuschle M. Intranasal insulinlike growth factor I (IGF-I) as a plausible future treatment of depression. Med Hypotheses. 2012; 79(2): 222-225.
43. Rajkowska G, Miguel-Hidalgo JJ. Gliogenesis and glial pathology in depression. CNS Neurol Disord Drug Targets. 2007; 6(3): 219-233. (Pubitemid 46916253)
44. Diniz BS, Teixeira AL, Miranda AS, et al. Circulating glial-derived neurotrophic factor is reduced in late-life depression. J Psychiatr Res. 2012; 46(1): 135-139.
45. Tseng PT, Lee Y, Lin PY. Age-associated decrease in serum glial cell line-derived neurotrophic factor levels in patients with major depressive disorder. Progr Neuropsychopharmacol Biol Psychiatry. 2013; 40: 334-339.
46. Zhang X, Zhang Z, Sha W, et al. Electroconvulsive therapy increases glial cell-line derived neurotrophic factor (GDNF) serum levels in patients with drugresistant depression. Psychiatry Res. 2009; 170(2-3): 273-275.
47. Liu Q, Zhu HY, Li B, et al. Chronic clomipramine treatment restores hippocampal expression of glial cell line-derived neurotrophic factor in a rat model of depression. J Affect Disord. 2012; 141(2-3): 367-372.
48. Otsuki K, Uchida S, Watanuki T, et al. Altered expression of neurotrophic factors in patients with major depression. J Psychiatr Res. 2008; 42(14): 1145-1153.
49. Golan M, Schreiber G, Avissar S. Antidepressants elevate GDNF expression and release from C(6) glioma cells in a beta-arrestin1-dependent, CREB interactive pathway. Int J Neuropsychopharmacol. 2011; 14(10): 1289-1300.
50. Uchida S, Hara K, Kobayashi A, et al. Epigenetic status of GDNF in the ventral striatum determines susceptibility and adaptation to daily stressful events. Neuron. 2011; 69(2): 359-372.
51. Svenningsson P, Chergui K, Rachleff I, et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science. 2006; 311(5757): 77-80. (Pubitemid 43063061)
52. Anisman H, Du L, Palkovits M, et al. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J Psychiatry Neurosci. 2008; 33(2): 131-141. (Pubitemid 351441383)
53. Warner-Schmidt JL, Chen EY, Zhang X, et al. A role for p11 in the antidepressant action of brain-derived neurotrophic factor. Biol Psychiatry. 2010; 68(6): 528-535.
54. Zhang L, Su TP, Choi K, et al. P11 (S100A10) as a potential biomarker of psychiatric patients at risk of suicide. J Psychiatr Res. 2011; 45(4): 435-441.
55. Su TP, Zhang L, Chung MY, et al. Levels of the potential biomarker p11 in peripheral blood cells distinguish patients with PTSD from those with other major psychiatric disorders. J Psychiatr Res. 2009; 43(13): 1078-1085.
56. Voleti B, Duman RS. The roles of neurotrophic factor and Wnt signaling in depression. Clin Pharmacol Ther. 2012; 91(2): 333-338.
57. Stamos JL, Weis WI. The b-catenin destruction complex. Cold Spring Harb Perspect Biol. 2013; 5(1). http://www. ncbi.nlm.nih.gov/pubmed/23169527.
58. Inestrosa NC, Arenas E. Emerging roles of Wnts in the adult nervous system. Nat Rev Neurosci. 2010; 11: 77-86.
59. Matrisciano F, Busceti CL, Bucci D, et al. Induction of the Wnt antagonist Dickkopf-1 is involved in stress-induced hippocampal damage. PLoS One. 2011; 6(1): e16447.
60. Voleti B, Tanis KQ, Newton SS, Duman RS. Analysis of target genes regulated by chronic electroconvulsive therapy reveals role for Fzd6 in depression. Biol Psychiatry. 2012; 71(1): 51-58.
61. Machado-Vieira R, Manji HK, Zarate CA Jr. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord. 2009; 11(suppl 2): 92-109.
62. Gould TD, Einat H, Bhat R, Manji HK. AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol. 2004; 7(4): 387-390. (Pubitemid 39648068)
63. O'Brien WT, Harper AD, Jove F, et al. Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J Neurosci. 2004; 24(30): 6791-6798. (Pubitemid 38993901)
64. Okamoto H, Voleti B, Banasr M, et al. Wnt2 expression and signaling is increased by different classes of antidepressant treatments. Biol Psychiatry. 2010; 68(6): 521-527.
65. Wilkinson MB, Dias C, Magida J, et al. A novel role of the WNT-dishevelled-GSK3beta signaling cascade in the mouse nucleus accumbens in a social defeat model of depression. J Neurosci. 2011; 31: 9084-9092.
66. Meffert MK, Baltimore D. Physiological functions for brain NF-kappaB. Trends Neurosci. 2005; 28(1): 37-43.
67. Frenois F, Moreau M, O'Connor J, et al. Lipopolysaccharide induces delayed FosB/DeltaFosB immunostaining within the mouse extended amygdala, hippocampus and hypothalamus, that parallel the expression of depressive-like behavior. Psychoneuroendocrinology. 2007; 32(5): 516-531. (Pubitemid 46756007)
68. Vialou V, Maze I, Renthal W, et al. Serum response factor promotes resilience to chronic social stress through the induction of DeltaFosB. J Neurosci. 2010; 30(43): 14585-14592.
69. McClung CA, Ulery PG, Perrotti LI, et al. DeltaFosB: a molecular switch for long-term adaptation in the brain. Brain Res Mol Brain Res. 2004; 132(2): 146-154. (Pubitemid 39586757)
70. Ohnishi YN, Ohnishi YH, Hokama M, et al. FosB is essential for the enhancement of stress tolerance and antagonizes locomotor sensitization by DeltaFosB. Biol Psychiatry. 2011; 70(5): 487-495.
71. Furmaga H, Sadhu M, Frazer A. Comparison of DeltaFosB immunoreactivity induced by vagal nerve stimulation with that caused by pharmacologically diverse antidepressants. J Pharmacol Exp Ther. 2012; 341(12): 317-325.
72. Li N, Lee B, Liu RJ, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science. 2010; 329(5994): 959-964.
73. Denk MC, Rewerts C, Holsboer F, Erhardt-Lehmann A, Turck CW. Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation. Am J Psychiatry. 2011; 168(7): 751-752.
74. Dwyer JM, Lepack AE, Duman RS. mTOR activation is required for the antidepressant effects of mGluR(2)/(3) blockade. Int J Neuropsychopharmacol. 2012; 15(4): 429-434.
75. Autry AE, Adachi M, Nosyreva E, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature. 2011; 475(7354): 91-95.
76. Monteggia LM, Gideons E, Kavalali ET. The role of eukaryotic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry In press. DOI: 10.1016/j.biopsych.2012.09.006.
77. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR D report. Am J Psychiatry. 2006; 163(11): 1905-1917. (Pubitemid 44807782)
78. Rush AJ, Trivedi MH, Stewart JW, et al. Combining medications to enhance depression outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. Am J Psychiatry. 2011; 168(7): 689-701.
79. Zarate CA Jr, Singh JB, Carlson PJ, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatmentresistant major depression. Arch Gen Psychiatry. 2006; 63(8): 856-864. (Pubitemid 44188478)
80. Zarate CA Jr, Mathews D, Ibrahim L, et al. A randomized trial of a low-trapping nonselective n-methyl-d-aspartate channel blocker in major depression. Biol Psychiatry In press. DOI: 10.1016/j.biopsych.2012.10.019.
81. McCarthy DJ, Alexander R, Smith MA, et al. Glutamatebased depression GBD. Med Hypotheses. 2012; 78(5): 675-681.